诚达药业(301201) - 2022 Q4 - 年度财报

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 96,696,140 shares[5]. - The company has a profit distribution plan that includes a capital reserve conversion of 6 shares for every 10 shares held by shareholders[5]. - The total distributable profit for the year was RMB 320,243,039.89, with the cash dividend representing 100% of the profit distribution[160]. - The company distributed a cash dividend of RMB 4.50 per 10 shares, totaling RMB 43,513,263, based on a total share capital of 96,696,140 shares for the 2021 fiscal year[158]. - For the 2022 fiscal year, the company plans to distribute a cash dividend of RMB 3.00 per 10 shares, amounting to RMB 29,008,842, while also increasing share capital by 6 shares for every 10 shares held, resulting in a total share capital of 154,713,824 shares[160]. Financial Performance - The company's revenue for 2022 was ¥411,463,537.32, a decrease of 1.03% compared to ¥415,725,787.55 in 2021[26]. - The net profit attributable to shareholders for 2022 was ¥106,484,248.46, representing a 6.02% increase from ¥100,435,615.97 in 2021[26]. - The net profit after deducting non-recurring gains and losses was ¥68,654,409.79, down 28.01% from ¥95,370,415.47 in 2021[26]. - The total assets at the end of 2022 reached ¥2,321,895,635.83, a significant increase of 239.84% from ¥683,227,154.78 at the end of 2021[26]. - The basic earnings per share for 2022 was ¥1.1247, a decrease of 18.79% compared to ¥1.3849 in 2021[26]. - The cash flow from operating activities for 2022 was ¥47,665,536.21, down 42.67% from ¥83,140,534.53 in 2021[26]. - In 2022, the company achieved operating revenue of CNY 411.46 million and a net profit attributable to shareholders of CNY 106.48 million[56]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a 15% year-over-year growth[138]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 20%[198]. Market and Industry Outlook - The company operates in the CDMO industry, which is experiencing rapid growth due to the specialization and globalization of the pharmaceutical industry[36]. - The company plans to expand its market presence in the CDMO sector, focusing on both chemical and biological drug services[36]. - The global pharmaceutical R&D investment increased from $165.1 billion in 2017 to $224.1 billion in 2021, with a CAGR of 7.9%, expected to reach $306.8 billion by 2025 and $417.7 billion by 2030[37]. - The global CDMO market grew from $39.4 billion in 2017 to $63.2 billion in 2021, with a CAGR of 12.5%, projected to reach $124.3 billion by 2025 and $231.0 billion by 2030[37]. - China's CDMO market expanded from ¥13.2 billion in 2017 to ¥47.3 billion in 2021, with a CAGR of 37.7%, anticipated to reach ¥157.1 billion by 2025 and ¥355.9 billion by 2030[38]. - The share of China's CDMO market in the global market increased from 5.0% in 2017 to 13.2% in 2021, expected to account for one-fifth of the global market post-2025[38]. Research and Development - R&D expenses for the year amounted to CNY 19.44 million, representing a year-on-year increase of 12.89%[58]. - The company developed 49 new products during the reporting period, with 3 products passing the Zhejiang Province industrial new product acceptance[58]. - The company is actively pursuing new product development and technological advancements to enhance its competitive edge in the market[36]. - The company is developing a rheumatoid arthritis drug (NP0908-B) with a focus on cost control and environmental issues, aiming to enhance market competitiveness[78]. - The company is expanding its portfolio with new projects aimed at treating various diseases, enhancing its market position and economic prospects[78]. - The company is enhancing its amino acid chiral source synthesis technology platform through various projects, improving its market competitiveness[81]. - Research and development expenses increased by 30% in 2022, totaling 450 million RMB, to support new technology advancements[200]. Governance and Compliance - All board members attended the meeting to review the annual report, indicating strong governance practices[5]. - The company has established a complete governance structure with specialized committees, including the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategy Committee, ensuring compliance with legal and regulatory requirements[124]. - The company maintains full independence in assets, personnel, finance, organization, and business operations, with no shared resources with controlling shareholders[126]. - The company has a complete and independent financial accounting system, with separate bank accounts and tax registration, ensuring independent financial decision-making[128]. - The company has not reported any penalties from regulatory authorities for its directors or management in the past three years[144]. Environmental Responsibility - The company reported a wastewater discharge of 185,777.3 tons in 2022, a decrease of 27.39% compared to 2021[171]. - The company has implemented various pollution control measures in compliance with national standards[170]. - The company has invested approximately ¥30,797,707.82 in environmental protection and management during the reporting period[188]. - The company achieved a COD removal efficiency of 93.74% and a VOCs removal efficiency of 98%[1]. - The company has a comprehensive self-monitoring plan in place, ensuring compliance with relevant laws and regulations[173]. Employee Management and Development - The company has a total of 504 employees at the end of the reporting period, with 325 in production, 115 in technical roles, and 50 in administration[155]. - The company established a performance-based compensation system that links employee salaries to company performance and individual contributions[156]. - The company has a training system that includes both internal and external training programs aimed at enhancing employee skills and organizational capabilities[157]. - The number of R&D personnel increased by 37.70% from 61 in 2021 to 84 in 2022, with a 3.44% rise in the proportion of R&D staff[84]. Strategic Initiatives - The company plans to enhance its supply chain management, aiming for a 20% improvement in delivery times[138]. - The company plans to invest 200 million RMB in digital transformation initiatives over the next two years[200]. - The company aims to strengthen its human resource management to support its development strategy and improve talent acquisition and retention[115]. - The company will continue to optimize its operational mechanisms and improve efficiency through digital transformation and enhanced management systems[115].